2009 Tuberculosis Drug Development GRC

2009年结核病药物开发GRC

• 批准号: 7666385
• 负责人: Eric J. Rubin
• 金额: $ 1.65万
• 依托单位: GORDON RESEARCH CONFERENCES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-23 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7666385
• 关键词: Academia; Area; Biology; Cause of Death; Chemistry; Clinical Research; Disease; Disease Resistance; Drug resistance; Drug-sensitive; England; Event; Funding; Industry; Pharmacology; Research; Research Personnel; Tuberculosis; drug development; experience; improved; meetings; symposium; tuberculosis drugs; tuberculosis treatment

DESCRIPTION (provided by applicant): This application seeks partial support for the 2009 Gordon Research Conference (GRC) on Tuberculosis (TB) Drug Development to be held in Oxford, England in August. This biennial event is the most important conference for bringing together researchers from both academia and industry. Treatment of TB remains a continuing challenge particularly with the increasing problem of drug resistance. New treatments could dramatically improve the results of therapy of both drug-sensitive and drug-resistant disease. This is an extremely active area of research and is increasingly attracting investigators with diverse biology, chemistry, pharmacology and clinical research backgrounds. The 2009 GRC on TB Drug Development will provide an opportunity for new investigators to understand the challenges in the field and for experienced researchers to discuss the latest findings.

描述（由申请人提供）：本申请寻求对八月在英格兰牛津举行的关于结核病（TB）药物开发的2009年戈登研究会议（GRC）的部分支持。这次两年一次的活动是将学术界和工业研究人员汇集在一起​​的最重要的会议。 TB的治疗仍然是一个持续的挑战，尤其是在耐药性问题日益增加的情况下。新疗法可以大大改善对药物敏感和耐药性疾病的治疗结果。这是一个非常活跃的研究领域，越来越吸引具有不同生物学，化学，药理学和临床研究背景的研究人员。 2009年的结核病药物开发GRC将为新调查人员提供一个了解该领域挑战的机会，并让经验丰富的研究人员讨论最新发现。